

DYNAVAX TECHNOLOGIES CORP  
Form 8-K  
May 27, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 5/27/2010**

**Dynavax Technologies Corporation**

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

**Delaware**  
(State or other jurisdiction

of incorporation)

**33-0728374**  
(IRS Employer

Identification No.)

2929 Seventh Street, Suite 100

Edgar Filing: DYNAVAX TECHNOLOGIES CORP - Form 8-K

Berkeley, CA 94710-2753

(Address of principal executive offices, including zip code)

(510) 848-5100

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On May 27, 2010, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue Immunizations - Second Safety Assessment Complete." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibit

**Exhibit**

**No.**

**Description**

|      |  |
|------|--|
| 99.1 | Press Release, dated May 27, 2010, titled "Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue Immunizations - Second Safety Assessment Complete." |
|------|--|

**Signature(s)**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DYNAVAX TECHNOLOGIES CORPORATION**

Date: May 27, 2010

By: /s/ **MICHAEL S. OSTRACH**  
**Michael S. Ostrach**

**Vice President**